Actual Situation and Characteristics of Pharmacotherapy for Glucocorticoid-induced Osteoporosis Prevention

  • Seiki Shizuno
    Laboratory of Pharmacy Practice and Community Healthcare, Gifu Pharmaceutical University
  • Yamashita Shuji
    Laboratory of Pharmacy Practice and Community Healthcare, Gifu Pharmaceutical University Gifu Pharmaceutical University Pharmacy
  • Kaburaki Miho
    Laboratory of Community Healthcare Pharmacy, Gifu Pharmaceutical University
  • Tamaki Hirofumi
    Gifu Pharmaceutical University Pharmacy Laboratory of Community Pharmacy, Gifu Pharmaceutical University
  • Noguchi Yoshihiro
    Gifu Pharmaceutical University Pharmacy Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University
  • Osanai Arihiro
    Gifu Pharmaceutical University Pharmacy Laboratory of Community Pharmacy, Gifu Pharmaceutical University
  • Ino Yoko
    Gifu Pharmaceutical University Pharmacy Laboratory of Community Pharmacy, Gifu Pharmaceutical University
  • Iguchi Kazuhiro
    Gifu Pharmaceutical University Pharmacy Laboratory of Community Pharmacy, Gifu Pharmaceutical University
  • Teramachi Hitomi
    Gifu Pharmaceutical University Pharmacy Laboratory of Community Healthcare Pharmacy, Gifu Pharmaceutical University Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University
  • Hayashi Hideki
    Laboratory of Pharmacy Practice and Community Healthcare, Gifu Pharmaceutical University Laboratory of Community Healthcare Pharmacy, Gifu Pharmaceutical University

Bibliographic Information

Other Title
  • ステロイド性骨粗鬆症予防に対する薬物療法の実態と特徴

Search this article

Description

<p>Glucocorticoid-induced osteoporosis (GIO) is a serious side effect of long-term glucocorticoid (GC) administration. However, sufficient high compliance rate data for the guidelines on the management and treatment of GIO in Japan is unavailable. Additionally, GC is prescribed at many medical departments involved in outpatient care. Community pharmacists might intervene to support more appropriate pharmacotherapy to avoid GIO. This study examines the actual state and characteristics of pharmacotherapy for GIO prevention. We investigated 136 patients from the Gifu Pharmaceutical University pharmacy that received GC treatment continuously for over three months. We obtained the age, GC dosage, and combined medications data retrospectively from the electronic drug system and assessed the fracture risk factor using a scoring system. One hundred and two patients were recommended for prophylactic pharmacotherapy based on the guidelines on the management and treatment of GIO. Nineteen patients (18.6%) did not receive this therapy. Thus, community pharmacists should consider proposing prescriptions using the guidelines and help support GIO prevention.</p>

Journal

References(17)*help

See more

Details 詳細情報について

Report a problem

Back to top